BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 28/10/1996

FDA Proposes to Revise Postmarketing Adverse Experience Reporting Regulations

The FDA is proposing to simplify postmarketing reporting of adverse experiences for human drugs and licensed biological products by eliminating the requirement for increased frequency reports, which the agency believes are no longer necessary for identifying safety problems.

Source: Federal Register — Food and Drug AdministrationOpen original release →